News | March 18, 2024
AstraZeneca to acquire Amolyt Pharma
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated
